JP2011506576A - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- JP2011506576A JP2011506576A JP2010538767A JP2010538767A JP2011506576A JP 2011506576 A JP2011506576 A JP 2011506576A JP 2010538767 A JP2010538767 A JP 2010538767A JP 2010538767 A JP2010538767 A JP 2010538767A JP 2011506576 A JP2011506576 A JP 2011506576A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- composition
- lubricant
- piperazin
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
Description
1. 処置を必要とする対象における、例えば、上記に示されているTリンパ球および/またはPKCが介在する障害または疾患の予防または処置において使用するための、上記定義のとおりの3−(1.H.−インドル−3−イル)−4−[2−(4−メチル−ピペラジン−1−イル)−キナゾリン−4−イル]−ピロール−2,5−ジオンまたはその薬学的に許容される塩を含む錠剤。
薬剤を希釈剤、結合剤、崩壊剤、流動促進剤(用途1−6)と混合し、自由落下混合機で混合する。この混合物を滑剤(用途7)と再び混合し、直接異なる強度の錠剤に圧縮する。
薬剤を希釈剤、結合剤、崩壊剤、流動促進剤(用途1−6)と混合し、自由落下混合機で混合する。この混合物を滑剤(用途7)と再び混合し、直接異なる強度の錠剤に圧縮する。この方法を介して得ることができる3つの組成物の例を表1aに示す。
次にこれらの錠剤を非機能性コーティング剤でコーティングする。
薬剤を希釈剤、結合剤、崩壊剤、流動促進剤(用途1−5)と混合し、滑剤(用途6)と一緒に混合し、第1の段階で錠剤またはリボンに圧縮し、適当な篩いを介して篩いにかけ、顆粒を得る。この顆粒を希釈剤、結合剤、崩壊剤および流動促進剤(用途7−10)の別の成分と再び混合し、適当な滑剤を混合物に加えた後に錠剤に圧縮する。
Claims (11)
- 3−(1.H.−インドル−3−イル)−4−[2−(4−メチル−ピペラジン−1−イル)−キナゾリン−4−イル]−ピロール−2,5−ジオンまたはその薬学的に許容される塩および少なくとも1種の滑剤を含む経口投与に適当な固体医薬組成物であって、ここで、該組成物が2から15重量%の滑剤を含み、該組成物が錠剤の形態であり、該組成物の総重量が全錠剤核重量である、固体医薬組成物。
- 組成物が全錠剤核重量に基づいて3から10重量%の滑剤を含む、請求項1に記載の組成物。
- 組成物が全錠剤核重量に基づいて5から90重量%の化合物を含む、請求項1に記載の組成物。
- 少なくとも1種の結合剤をさらに含む、請求項1または2に記載の組成物。
- 組成物が全錠剤核重量に基づいて4から40重量%の結合剤を含む、請求項3に記載の組成物。
- 少なくとも1種の増量剤をさらに含む、請求項1から5のいずれかに記載の組成物。
- 崩壊剤、流動促進剤および界面活性剤から選択される少なくとも1種のさらなる賦形剤を含む、請求項1から6のいずれかに記載の組成物。
- 3−(1.H.−インドル−3−イル)−4−[2−(4−メチル−ピペラジン−1−イル)−キナゾリン−4−イル]−ピロール−2,5−ジオンの酢酸塩を含む、請求項1から7のいずれかに記載の組成物。
- 処置の必要な対象におけるTリンパ球および/またはPKCが介在する障害または疾患の予防または処置において使用するための、請求項1から7のいずれかに記載の組成物。
- (a)3−(1.H.−インドル−3−イル)−4−[2−(4−メチル−ピペラジン−1−イル)−キナゾリン−4−イル]−ピロール−2,5−ジオンまたはその薬学的に許容される塩を結合剤、増量剤および所望により、崩壊剤および流動促進剤から選択される少なくとも1種のさらなる賦形剤と混合し;(b)(a)において得られた混合物を混合、緻密化、粉砕、造粒、乾燥または緻密化し;(c)(b)において得られた混合物を滑剤と混合し;(d)打錠し、そして(e)所望によりコーティングすることを含む、請求項1から7のいずれかに記載の錠剤を製造するための方法。
- (a)水溶液中で増量剤、結合剤および所望により崩壊剤を混合し、そして得られた混合物を造粒し;
(b)(a)において得られた顆粒を乾燥および粉砕し、そしてそれらを滑剤と混合し;
(c)所望により3−(1.H.−インドル−3−イル)−4−[2−(4−メチル−ピペラジン−1−イル)−キナゾリン−4−イル]−ピロール−2,5−ジオンまたはその薬学的に許容される塩を増量剤、崩壊剤、流動促進剤、結合剤および滑剤から選択される少なくとも1種のさらなる賦形剤と混合し;
(d)3−(1.H.−インドル−3−イル)−4−[2−(4−メチル−ピペラジン−1−イル)−キナゾリン−4−イル]−ピロール−2,5−ジオンまたはその薬学的に許容される塩を直接または工程(c)で得られた混合物のいずれかを工程(b)において得られた顆粒と、所望により滑剤の存在下で混合し;
(e)工程(b)、(c)または(d)において得られた混合物を打錠し;そして
(f)所望によりコーティングする
ことを含む、請求項1から7のいずれかに記載の錠剤を製造するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07150347 | 2007-12-21 | ||
EP07150347.8 | 2007-12-21 | ||
PCT/EP2008/068051 WO2009080762A2 (en) | 2007-12-21 | 2008-12-19 | Pharmaceutical composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013236787A Division JP2014040477A (ja) | 2007-12-21 | 2013-11-15 | 医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011506576A true JP2011506576A (ja) | 2011-03-03 |
JP5525453B2 JP5525453B2 (ja) | 2014-06-18 |
Family
ID=39495348
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010538767A Expired - Fee Related JP5525453B2 (ja) | 2007-12-21 | 2008-12-19 | 医薬組成物 |
JP2013236787A Pending JP2014040477A (ja) | 2007-12-21 | 2013-11-15 | 医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013236787A Pending JP2014040477A (ja) | 2007-12-21 | 2013-11-15 | 医薬組成物 |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100316713A1 (ja) |
EP (1) | EP2240164A2 (ja) |
JP (2) | JP5525453B2 (ja) |
KR (1) | KR20100103625A (ja) |
CN (1) | CN101883558A (ja) |
AR (1) | AR069799A1 (ja) |
AU (1) | AU2008340019B2 (ja) |
BR (1) | BRPI0820839A2 (ja) |
CA (1) | CA2709909A1 (ja) |
CL (1) | CL2008003823A1 (ja) |
CO (1) | CO6382170A2 (ja) |
EC (1) | ECSP10010360A (ja) |
IL (1) | IL205931A0 (ja) |
MA (1) | MA31950B1 (ja) |
MY (1) | MY158293A (ja) |
NZ (1) | NZ586313A (ja) |
PE (1) | PE20091522A1 (ja) |
RU (1) | RU2485951C2 (ja) |
TN (1) | TN2010000243A1 (ja) |
TW (1) | TWI449541B (ja) |
WO (1) | WO2009080762A2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR069799A1 (es) * | 2007-12-21 | 2010-02-17 | Novartis Ag | Composicion farmaceutica |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531625A (ja) * | 2005-03-01 | 2008-08-14 | ノバルティス アクチエンゲゼルシャフト | インドリルマレイミド誘導体を含む医薬組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ323571A (en) * | 1995-11-20 | 1998-12-23 | Lilly Co Eli | Protein kinase c inhibitor |
TW200918046A (en) * | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
AU2006252553B2 (en) * | 2005-06-02 | 2012-03-29 | Merck Sharp & Dohme Corp. | Combination of HCV protease inhibitors with a surfactant |
BRPI0613611A2 (pt) * | 2005-07-22 | 2011-01-18 | Myriad Genetics Inc | formulações de alta concentração de fármaco e formas de dosagens |
US7762932B2 (en) * | 2007-09-17 | 2010-07-27 | Fitness Anywhere, Inc. | Inelastic exercise device having a limited range |
AR069799A1 (es) * | 2007-12-21 | 2010-02-17 | Novartis Ag | Composicion farmaceutica |
-
2008
- 2008-12-18 AR ARP080105520A patent/AR069799A1/es unknown
- 2008-12-18 PE PE2008002124A patent/PE20091522A1/es not_active Application Discontinuation
- 2008-12-19 RU RU2010129544/15A patent/RU2485951C2/ru not_active IP Right Cessation
- 2008-12-19 CA CA2709909A patent/CA2709909A1/en not_active Abandoned
- 2008-12-19 MY MYPI2010002374A patent/MY158293A/en unknown
- 2008-12-19 EP EP08865096A patent/EP2240164A2/en not_active Withdrawn
- 2008-12-19 CL CL2008003823A patent/CL2008003823A1/es unknown
- 2008-12-19 BR BRPI0820839-5A patent/BRPI0820839A2/pt not_active IP Right Cessation
- 2008-12-19 KR KR1020107016148A patent/KR20100103625A/ko not_active Application Discontinuation
- 2008-12-19 US US12/808,905 patent/US20100316713A1/en not_active Abandoned
- 2008-12-19 WO PCT/EP2008/068051 patent/WO2009080762A2/en active Application Filing
- 2008-12-19 NZ NZ586313A patent/NZ586313A/xx not_active IP Right Cessation
- 2008-12-19 CN CN2008801190561A patent/CN101883558A/zh active Pending
- 2008-12-19 AU AU2008340019A patent/AU2008340019B2/en not_active Ceased
- 2008-12-19 TW TW097149851A patent/TWI449541B/zh not_active IP Right Cessation
- 2008-12-19 JP JP2010538767A patent/JP5525453B2/ja not_active Expired - Fee Related
-
2010
- 2010-05-24 IL IL205931A patent/IL205931A0/en unknown
- 2010-05-28 TN TN2010000243A patent/TN2010000243A1/fr unknown
- 2010-06-29 MA MA32969A patent/MA31950B1/fr unknown
- 2010-07-20 EC EC2010010360A patent/ECSP10010360A/es unknown
- 2010-07-21 CO CO10088697A patent/CO6382170A2/es not_active Application Discontinuation
-
2013
- 2013-11-15 JP JP2013236787A patent/JP2014040477A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531625A (ja) * | 2005-03-01 | 2008-08-14 | ノバルティス アクチエンゲゼルシャフト | インドリルマレイミド誘導体を含む医薬組成物 |
Non-Patent Citations (2)
Title |
---|
"第1部 剤形論(物理薬剤学)", 新・薬剤学総論(改訂第3版), vol. 第1版, JPN6013013493, 1987, pages 138 - 140, ISSN: 0002487663 * |
改訂 医薬品添加物ハンドブック, JPN6013013491, 9 August 2005 (2005-08-09), pages 471 - 475, ISSN: 0002487662 * |
Also Published As
Publication number | Publication date |
---|---|
IL205931A0 (en) | 2010-11-30 |
WO2009080762A3 (en) | 2009-09-11 |
JP5525453B2 (ja) | 2014-06-18 |
US20100316713A1 (en) | 2010-12-16 |
RU2485951C2 (ru) | 2013-06-27 |
CO6382170A2 (es) | 2012-02-15 |
AU2008340019B2 (en) | 2012-05-03 |
RU2010129544A (ru) | 2012-01-27 |
PE20091522A1 (es) | 2009-10-29 |
TW200940106A (en) | 2009-10-01 |
NZ586313A (en) | 2012-08-31 |
MA31950B1 (fr) | 2010-12-01 |
CA2709909A1 (en) | 2009-07-02 |
TWI449541B (zh) | 2014-08-21 |
JP2014040477A (ja) | 2014-03-06 |
WO2009080762A2 (en) | 2009-07-02 |
CN101883558A (zh) | 2010-11-10 |
EP2240164A2 (en) | 2010-10-20 |
AR069799A1 (es) | 2010-02-17 |
TN2010000243A1 (en) | 2011-11-11 |
KR20100103625A (ko) | 2010-09-27 |
ECSP10010360A (es) | 2010-08-31 |
BRPI0820839A2 (pt) | 2015-06-16 |
CL2008003823A1 (es) | 2010-01-22 |
AU2008340019A1 (en) | 2009-07-02 |
MY158293A (en) | 2016-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8435564B2 (en) | Pharmaceutical compositions comprising brivaracetam | |
CN106943355B (zh) | 药物组合物 | |
WO2017140254A1 (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
AU2006220056B2 (en) | Pharmaceutical composition comprising an indolylmaleimide derivative | |
JP6895779B2 (ja) | アジルサルタン含有固形医薬組成物 | |
JP2015511635A (ja) | オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物 | |
EP3027174A1 (en) | Pharmaceutical compositions of fingolimod | |
WO2014080384A1 (en) | Pharmaceutical composition of linagliptin | |
EP2867199B1 (en) | Stable compositions of fesoterodine | |
JP5525453B2 (ja) | 医薬組成物 | |
AU2013366640A1 (en) | Tablet composition comprising cinacalcet hydrochloride | |
US20150297603A1 (en) | HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER | |
JP2011527316A (ja) | 直接打錠によるアリスキレン錠剤 | |
JP2022140430A (ja) | リバーロキサバン含有錠剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130621 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131115 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140325 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140411 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5525453 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |